Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)

September 11, 2026 6:59 AM
H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating and $10.00 price target on Biohaven Pharma (NYSE: BHVN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments